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Structural approaches have provided important insights into immune mechanisms and the
complexity of host-pathogen interactions. This Select highlights recent studies that have, through
varied structural and molecular modeling approaches, revealed fascinating aspects of innate and
adaptive immunity and the strategies used by pathogens to circumvent them.RNase L forms a homodimer,
which assembles a dimeric
active site. IRE1 uses similar
sequence rules with RNase L
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Upon infection, cellsof higher vertebratesproduce interferons (IFNs),whichactivate variousantiviral
programs in the infectedcell andsurroundingcells, thus limiting the spreadof infection.Oneof these
antiviral mediators is RNase L, an endoribonuclease that cleaves viral and cellular RNA on demand.
RNase L is activated by 2’,5’-linked oligoadenylates (2-5A), products of IFN-inducible 2-5A synthe-
tases,which in turn are sensors for double-strandedRNA (dsRNA) resulting fromcellular damageor
viral infection. RNase L thus integrates infection signals from IFNs and dsRNA. Two studies now
provide a precise molecular view of RNase L and shed light into the recently emerged functions
of the related receptor IRE1, which mitigates stress caused by unfolded protein overload of the
endoplasmic reticulum (ER) by cleaving transcripts encoding membrane and secreted proteins.
Huang et al. (2014) show, by structural analysis of porcine RNase L in complex with 2-5A and a non-
hydrolysable ATPmimetic (AMP-PNP), that RNase L forms a specific dimer configuration that juxta-
poses the two RNase domains and creates the enzyme’s catalytic site. The authors propose that
dimerization of inactive RNase Lmonomers occurs upon 2-5Abinding and that the binding of abun-dant cellular nucleotides ATP/ADP further adds rigidity to the structure that is required for catalytic function. In a related study, Han
et al. (2014) solve the crystal structure of human RNase L in complex with an RNA substrate. As with the Huang et al. study, the ho-
modimer reveals a surprising third binding site for 2-5A in a composite pocket created by the ankyrin and kinase homology domains.
Thiswork suggests that RNaseL uses its dimeric active site for asymmetric RNA recognition. Structural and biochemical analyses of
the catalytic site, comprisedwithin the interface of KEN/KEN (kinase extension nuclease) dimers, explain the cleavage site selection
inhostandviralRNA. IRE1shares theKENmoduleofRNaseL,andanalysesof IRE1 target transcripts revealssimilarities insequence
determinants suggesting commonality at some level in the substrate recognition and cleavagemechanisms used by both enzymes.
These findings also open opportunities for the design of RNase L agonists or antagonists aimed at modulating the IFN response.
Huang, H., et al. (2014). Mol Cell. 53, 221–234.
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Complement is an important layer of host immune surveillance and defense against patho-
gens. The classical pathway of complement activation involves binding of C1q to antigen-
bound immunoglobulin M (IgM) or IgG molecules. This binding triggers the activation of
proteases within the C1 complex and the initiation of the complement cascade that culmi-
nates in the activation of varied effector mechanisms aimed at pathogen clearance. IgM
molecules exist mostly in pentamers, and this polymeric state increases the avidity of C1q
binding. However, IgM requires a conformational change upon antigen binding for C1q-bind-
ing sites to become exposed. In IgG, C1q-binding sites are continuously exposed but the
affinity is very low, presumably to avoid binding in the blood. Diebolder and colleagues now
providemolecular insight on how IgG interacts efficiently with C1q and activates complement.
On basis of structural studies, the authors hypothesized that after binding antigen, IgG mole-
cules form hexamers, thus providing scaffolds for efficient complement activation. Mutations
in the Fc interphase designed to manipulate noncovalent Fc-Fc interactions between IgGmol-
eculessignificantlydecreasedor increasedcomplementdependentcytotoxicity.Cryo-electron
tomography of antigen-bound IgG on amembrane revealed a hexagonal arrangement with C1
bound. Interestingly,modelingof theC1-antibodyhexamercomplex suggested thatonlyoneof
the twoFabarmsof theantibody isbound to theantigen.Bispecificantibodies,designedso that
one arm recognizes the antigen and the other is irrelevant for that interaction, could induce su-
perior complementactivationcompared toparental antibodies, providing insight into thegeom-
etryof these interactions. Theauthorsproposeamodelwhereinantigenbindingby IgG followed
byFc-Fcbinding leads to the formationof hexamers resulting inhighaviditybindingofC1q.This
suggests that this multimerization may provide a checkpoint, so that complement is activated
only after target binding. These findings also reveal an exciting strategy for designing more effective therapeutic antibodies.
Diebolder, C.A., et al. (2014). Science. 343, 1260–1263.Cell 157, April 24, 2014 ª2014 Elsevier Inc. 521
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Immunoglobulin E (IgE) molecules play important roles in immunity to parasites and in
the pathology of allergic diseases. IgE binds the FcεRI receptor on mast cells and baso-
phils, and antigen recognition by FcεRI-bound IgE triggers the release of inflammatory
mediators such as histamine. Previous structural and biophysical analyses revealed
an extraordinary, acute, and asymmetrical bend in the Fc region of the molecule. This
bent conformation has shaped current thinking of IgE’s functions. However, biophysical
analyses of Fab fragments of omalizumab (Xolair, Novartis Pharmaceuticals), an anti-igE
monoclonal antibody that is effective in the treatment of asthma and other allergic dis-
eases, suggested that IgE may not always exist in this acutely bent conformation. In a
recent study, Drinkwater et al. (2104) capture a fully extended conformation of IgE, pro-
voking a re-examination of how IgE works in vivo.
In IgG molecules, the antigen-binding Fab segments are connected to the receptor-
binding Fc chains via a flexible linker. The Fc regions of IgE molecules contain an addi-
tional pair of domains, (Cε2)2 in place of this flexible linker; in the bent conformation, the
Cε2 domain pair is folded back onto the Cε3-Cε4 domains. The authors generated an
IgG antibody Fab fragment that binds IgE-Fc (aεFab), and resolution of the crystal struc-
ture of aεFab-bound IgE-Fc reveals an extended, symmetrical conformation more
similar to that of IgG molecules. Using molecular dynamics simulations and a variety
of biophysical measurements, the authors show that this extended conformation isfound in solution and would result, at a molecular level, from a ‘‘flipping’’ of the Cε2 domains from one side of the molecule to
the other. Interestingly, allosteric constraints prevent this extended conformation from binding to the FcεRI receptor. Molecular
modeling approaches suggest that the membrane-bound IgE, which would function as a B cell receptor, displays an extended
conformation. Further studies should reveal how this conformational diversity impacts the biological functions of IgE.
Drinkwater, N., et al. (2014). Nat. Struct. Mol. Biol. 21, 397–404.Structure of the OspG/UbcH5cUb
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Upon infection, the human pathogen Shigella spp injects an array of bacterial effector
proteins into the host cell. These proteins in turnmanipulate host pathways so as to facil-
itate bacterial entry and survival and replication, and many of them act to inhibit innate
immune pathways in the cell. One of these effector proteins is the kinase OspG, which
inhibits degradation of a negative regulator of the NFkB pathway. To be effective in the
host-cell environment, bacterial enzymes are thought be highly active. OspG, however,
exhibits weak kinase activity in vitro. In a recent study, Pruneda et al. reveal that OspG
binds to and repurposes host E2Ubiquitin (Ub) conjugates, using this interaction to
enhance its kinase activity. The authors cocrystallized OspG in complex with
UbcH5c-OUb, showing that OspG interacts with both UbcH5c and Ub. These interac-
tions stabilize the kinase, compensating for the minimal intraprotein interactions within
OspG itself and providing context for OspG’s minimal kinase domain. Furthermore,
the stabilized structure is highly active. The authors show that OspG can interact with
various E2Ub conjugates. Effector kinases from Yersinia and enterohemorrhagic
E. coli exhibit high-sequence homology to OspG. Thus, the co-opting mechanism iden-
tified may be broadly used by bacterial pathogens.
Pruneda, J.N., et al. (2014). EMBO J. 33, 437–449.
Fabiola V. Rivas
Editor, Trends in ImmunologyCell 157, April 24, 2014 ª2014 Elsevier Inc. 523
